The subject matter disclosed herein relates to a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject with a Blood Disorder a composition targeting a telomerase in a Giant Cell of the Disorder.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A resonator constructed with one or more Van der Waals materials. In some embodiments, a system includes such a resonator. The resonator includes: a capacitor (305); and an inductor, the capacitor including: a first conductive layer (205); an insulating layer (215), on the first conductive layer; and a second conductive layer (220) on the insulating layer, the first conductive layer being composed of one or more layers of a first van der Waals material, the insulating layer being composed of one or more layers of a second van der Waals material, and the second conductive layer being composed of one or more layers of a third van der Waals material.
he present invention provides methods for using an anionic manganese oxide (MnO) nanoparticle-based nucleic acid scavenger to (1) inhibit viral infection of cells, (2) reduce or inhibit a viral infection of a subject, and (3) reduce viral infection induced inflammation in a subject.
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
A van der Waals capacitor and a qubit constructed with such a capacitor. In some embodiments, the capacitor includes a first conductive layer; an insulating layer, on the first conductive layer; and a second conductive layer on the insulating layer. The first conductive layer may be composed of one or more layers of a first van der Waals material, the insulating layer may be composed of one or more layers of a second van der Waals material, and the second conductive layer may be composed of one or more layers of a third van der Waals material.
G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
H01L 27/18 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including components exhibiting superconductivity
H01L 39/22 - Devices comprising a junction of dissimilar materials, e.g. Josephson-effect devices
Devices and methods for joining a first and second tissue in a patient are disclosed that include a base with a plurality of recurved tines oriented to a tine axis and extending from a first surface of the base. The tines provide unidirectional traction of the first tissue along the tine axis toward the first surface. The first tissue is secured to the first surface of the device at the plurality of recurved tines and the second tissue is secured to the device at a second surface opposite the first surface to join the first and second tissues.
A61D 1/00 - Surgical instruments for veterinary use
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
6.
GAS SEPARATION MEMBRANES FROM POLYMER-GRAFTED NANOPARTICLES
Gas separation membranes as may be used in separating gaseous materials from one another and methods of forming the membranes are described. The separation membranes include polymer-grafted nanoparticles (GNPs) as a platform and a relatively small amount of free polymer. The free polymer and the polymer grafted to the nanoparticles have the same chemical structure and similar number average molecular weights. The gas separation membranes can exhibit high ideal selectivity and can be used in a variety of applications, such as carbon capture.
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
A method for determining if a subject with cancer or precancerous lesions or a benign tumor, will respond to treatment with an inhibitor selected from the group comprising an inhibitor of one or more enzymes in the mevalonate pathway, an inhibitor of geranylgeranyl transferase, an inhibitor of farnesyl transferase or an inhibitor of squalene synthase, by (i) obtaining a sample of the cancer cells, precancerous cells or benign tumor cells from the subject, (ii) assaying the cells in the sample for the presence of a mutated p53 gene or a mutant form of p53 protein or a biologically active fragment thereof, and (iii) if the cells have the mutated p53 gene or mutant form of the p53 protein, then determining that the subject will respond to treatment with the inhibitor or combinations thereof. Some embodiments are directed to treatment with the inhibitors.
A method and apparatus include preparing a library of molecules that can be sequenced. The library includes multiple instances of each possible member of a k-mer. The library is sequenced to determine the relative frequency of each member of the k-mer in the library. The library is contacted with a biochemical system. A population of output molecules is sequenced to determine the relative frequency of each member of the k-mer in the population of output molecules. Each output molecule is related to a product of a process of the biochemical system and carries a k-mer related to a corresponding k-mer of a library molecule involved in the process. Effectiveness of each member of the k-mer is determined based on the relative frequency of each member of the k-mer in the population of output molecules and in the library.
Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
10.
METHODS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF CANCER INVOLVING MIRNAS AND MIRNA INHIBITORS AND TARGETS
The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
Microfabricated microvalves may be used with liquid-filled control channels and actuated using compact and battery-powered components, without the need for heavier or fixed infrastructure. The disclosed embodiments include microvalves with on-off fluid control with relatively fast response times, coordinated switching of multiple valves, and operation of a biological (enzyme- substrate) assay in a handheld configuration.
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Cohen, Ira S.
White, Thomas W.
Robinson, Richard B.
Brink, Peter R.
Mathias, Richard T.
Rosen, Michael R.
Abstract
The present invention provides a method for testing the efficiency of delivering an inhibitory polynucleotide to a target cell or tissue. The invention also provides a method for testing efficiency of delivering and efficacy for an effect on tumor size of an inhibitory polynucleotide against a target gene.
A monochromator is adapted to select at least one band of wavelengths from diverging incident radiation. The apparatus includes a first crystal and a second crystal. A band of emitted wavelengths of the first crystal is adapted to the at least one band of wavelengths. A surface curvature of the first crystal is adapted to focus emitted radiation in a first plane. A band of emitted wavelengths of the second crystal also is adapted to the at least one band of wavelengths. Parallel faces of a lattice structure of the second crystal are oriented at a first predetermined angle from a surface of the second crystal. In another embodiment, an apparatus is adapted to select at least one band of wavelengths from diverging incident synchrotron radiation in a given range of wavelengths with an energy resolution finer than about five parts in 10000 and optical efficiency greater than about 50 percent.
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
14.
METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2
Methods for treating eating disorders associated with excessive weight gain, suppressing appetite, reducing body weight, or treating obesity in an animal by administering one or more antagonists of the serotonin Htr1a or Htr2b receptor, or a Tph2 inhibitor are provided, or combinations thereof.
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
15.
CORONARY SINUS CANNULA WITH LEFT VENTRICLE LEAD AND PRESSURE TENT
Techniques for biventricular pacing include a rigid shaped stylet approximating curves of a coronary sinus and branch vein. Some techniques include a parasternal coronary sinus cannula comprising an outer sheath and an obturator. The obturator is removeably disposed inside the outer sheath from a device end of the hollow shaft. The obturator includes a flexible stem that fits snugly inside the hollow shaft, a malleable core disposed inside the flexible stem, a tapered tip that extends beyond a cardiac end of the shaft when the obturator is disposed inside the outer sheath, and a sensor for determining properties of the subject in a vicinity of the tapered tip. An optional pressure-seal, such as a tent, connected to suction maintains negative intrepleural pressure for insertion under local anesthesia.
A device generates a light barrier that can be used for different purposes. The barrier consists of one or more surfaces (or volume) exhibiting an abrupt change in light intensity. In some embodiments the change in intensity affects animals, including insects, approaching or crossing it. In some embodiments, the light generates thermal or density variations in the air that cause air movements that perturb particles, such as pollen, or other pests to human activity. In some embodiments, an approach includes an optical barrier generator configured to emit light of an optical waveform above a threshold power in a portion of space positioned relative to the generator. The optical waveform above the threshold power is effective at perturbing a pest to human activity.
Disclosed is a microarray of binary nucleic acid probes for the detection of one or a plurality of nucleic acid analytes in a complex sample in a single high throughput assay with extraordinary specificity under physiologic conditions Binary nucleic acid probes that generate a detectable signal when bound to analyte are suitable for use in the micro arrays, including binary deoxyribozyme or ribozyme probes, nonenzymatic binary probes for fluorescent detection, nonenzymatic binary dye-binding probes, and binary split enzyme peroxidase probes for visual detection of nucleic acids Nonenzymatic binary probes that bind to reporter oligonucleotides are also disclosed.
A strong association between variants in Elongator Protein Complex 4, (ELP4) (specifically single nucleotide polymorphisms, SNPs) at the 11p13 locus on chromosome 11 and the centrotemporal sharp wave trait (CTS) has been discovered, which association has diagnostic significance for rolandic epilepsy. It has further been discovered that the 11p13 locus has a pleiotropic role in the development of speech motor praxis and CTS, which supports a neurodevelopmental origin for classic rolandic epilepsy (RE).
A probe that changes solution color in the presence of only one of the two DNA sequences, which differ by a single nucleotide, is reported. The probe consists of two oligodeoxyribonucleotides, which form a hydrogen peroxidase-like DNA enzyme when hybridized to the abutting fragments of the complementary analyte. The active peroxidase catalyses oxidation of colorless substrates to the colored products. The probe allows visual detection of a mutation in Alzheimer's disease-related DNA.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
20.
APPLYING TORQUE TO PARAMAGNETIC STRUCTURES IN BODIES USING DUAL MAGNETIC FIELDS
Techniques for applying torque to microscopic paramagnetic structures in a body includes exposing a body simultaneously to a first magnetic field oscillating at a first frequency in a first direction and a different second magnetic field oscillating at a second frequency in a second direction. The body includes a plurality of microscopic paramagnetic structures for which magnetic susceptibility to the first magnetic field is different from magnetic susceptibility to the second magnetic field. Such techniques are effective for ameliorating a symptom of a disease in an animal in which disease agents or diseased cells selectively include microscopic paramagnetic structures, including malaria.
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
22.
METHODS FOR TREATING ADULT RESPIRATORY DISTRESS SYNDROME
We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter 'FAKp') strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.
Methods and systems forming biocompatible materials are disclosed herein. Forming a biocompatible material may include contacting a liquid, having a linking material, with an adjoining material having embedded therein a nucleating material that causes the linking material to nucleate and grow into the liquid. After a time sufficient to cause the linking material to grow substantially from the nucleating material into a space occupied by the liquid, the liquid may be solidified to form a solid such that the linking material secures the solid to the adjoining material.
The present invention is directed to methods for treating or preventing Alzheimer's disease by administering therapeutically effective amounts of an agent that reduces Cyclophilin D expression in a patient, or that reduce Cyclophilin D activity or its ability to form a complex with Amyloid beta. Such agents include antisense nucleotides and small interfering RNAs, antibodies that selectively bind to Cyclophilin D, and cyclosporine A and D.
We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell -mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.
A method for securing a gastric bypass sheath to the stomach. The sheath is passed into the stomach such that the sheath extends between the esophagus and the pylorus. The sheath is endoscopically anchored to the wall of a portion proximate the esophagus and to the wall of a portion proximate the pylorus. The tissue anchors may include a mesh bolster at the end outside of the gastrointestinal tract. The method may also include surgically forming a gastric bypass that encloses the sheath.
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
Inventor
Mayeux, Richard
Rogaeva, Ekaterina
St. George-Hyslop, Peter
Farrer, Lindsay
Abstract
The present invention is directed to a method for treating Alzheimer's disease in a patient who is also determined to have less than about 90% of the SORL1 level determined in a normal subject, by administering to the patient one or more of compounds that increase SORL1 expression in the patient.
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
The invention is directed to a new composition for making a housing block for cryosectioning comprising agarose and optimal cutting temperature medium. The invention is further directed to new methods for making a frozen section microarray of fresh non-fixed frozen cell or tissue samples that undergo only one freeze-thaw cycle before being used in a biological assay.
New binary deoxyribozyme or ribozyme probes and methods are described for nucleic acid analysis, which allows the detection of nucleic acids under mild physiologic conditions with extraordinary specificity and high sensitivity to single nucleotide mismatches without PCR amplification.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
30.
THE SORTILIN-RELATED RECEPTOR SORL1 IS FUNCTIONALLY AND GENETICALLY ASSOCIATED WITH ALZHEIMER'S DISEASE
The present invention relates methods for determining if a patient is at risk of developing Alzheimer's Disease by analyzing DNA from the patient and determining whether there are nucleotide variants in the region of the gene for SORL1 at SNP sites 4 or 8-12 and 19-26.
Certain aspects of the present invention are directed to a new cell-based assay that measures the level of biologically active FSH in a sample based on its ability to bind to and activate FSH receptors (hFSHR) on the cell surface, thereby eliciting an increase in cAMP production that can be measured using commercial RIAs and compared to a standard curve. Other aspects are directed to the use of the measurement of the level of bioactive FSH for determining ovarian reserve and candidates for fertility treatment.
Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.
It has been discovered that vascularized tissue or organs can be engineered by combined actions of tissue progenitor cells and vascular progenitor cells. Provided herein are compositions and methods directed to engineered vascularized tissue or organs formed by introducing tissue progenitor cells and vascular progenitor into or onto a biocompatible scaffold of matrix material. Also provided are methods of treating tissue defects via grafting of such compositions into subjects in need thereof.
A61F 2/01 - Filters implantable into blood vessels
C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.
The invention relates to methods and compositions for treating cystic fibrosis and P. aeruginosa infections by administering a therapeutic amount of one or more agents that inhibit de novo sphingolipid synthesis or recycling pathways.
A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.
C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
37.
BINARY PROBES FOR FLUORESCENT ANALYSIS OF NUCLEIC ACIDS
The invention is directed to binary oligonucleotide probes for nucleic analysis, which probes can be made of DNA or RNA that recognize nucleic acid analytes (both DNA and RNA) with unprecedented high selectivity under mild conditions and are highly sensitive to single nucleotide mismatches (SNP single nucleotide polymorphisms) without PCR amplification. In one group, the binary probes indicate that they have hybridized to a particular nucleic analyte by binding to a molecular beacon that gives off a fluorescent signal. A second group of binary probes bind to a dye such as malachite green, where upon hybridization to analyte the fluorescence of the dye increases dramatically and is easily detected and measured. The new binary probes require only about five minutes at room temperature to generate a detectable signal.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
38.
COLORIMETRIC LIGHT SWITCHING PROBE FOR ULTRASENSITIVE DETECTION OF TARGET COMPOUNDS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
COLUMBIA UNIVERSITY (USA)
Inventor
Tan, Weihong
Yang, Chaoyong
Vicens, Marie, C.
Turro, Nicholas, J.
Jockusch, Steffen
Abstract
A system and method for detecting a target compound, comprising an aptamer having a high affinity for the target compound, wherein two labels are attached to the aptamer. The two labels cause the probe to emit a baseline, non-visible emission. When the aptamer (also referred to herein as a probe) of the invention interacts with a target compound, the probe undergoes a conformational change, causing the fluorescence emission to change from the baseline emission to an emission that is detectable.
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
patents